1. Home
  2. INCY vs UTHR Comparison

INCY vs UTHR Comparison

Compare INCY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Incyte Corp.

INCY

Incyte Corp.

N/A

Current Price

$114.90

Market Cap

24.5B

Sector

Health Care

ML Signal

N/A

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

N/A

Current Price

$553.92

Market Cap

23.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INCY
UTHR
Founded
1991
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Commercial Physical & Biological Resarch
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5B
23.9B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
INCY
UTHR
Price
$114.90
$553.92
Analyst Decision
Buy
Buy
Analyst Count
28
15
Target Price
$132.17
★ $687.14
AVG Volume (30 Days)
★ 1.5M
424.2K
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 4173.33
13.07
EPS
0.50
★ 18.80
Revenue
★ $3,394,635,000.00
$1,483,300,000.00
Revenue This Year
$17.74
$2.15
Revenue Next Year
$4.38
$11.39
P/E Ratio
$231.80
★ $29.74
Revenue Growth
★ 13.67
2.38
52 Week Low
$89.25
$455.63
52 Week High
$132.60
$614.23

Technical Indicators

Market Signals
Indicator
INCY
UTHR
Relative Strength Index (RSI) 41.81 41.91
Support Level $109.78 $525.83
Resistance Level $119.29 $584.47
Average True Range (ATR) 3.73 19.66
MACD -0.53 -5.98
Stochastic Oscillator 3.94 4.97

Price Performance

Historical Comparison
INCY
UTHR

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: